#1 Clinical Trials Search in Europe

Humanised Igg1 Monoclonal Antibody Against Human Latent Myostatin

This article discusses ongoing clinical trials investigating the use of a humanised IgG1 monoclonal antibody against human latent myostatin in patients with muscular disorders. The drug, known as RO7204239, is being studied for its potential benefits in treating conditions such as Facioscapulohumeral Muscular Dystrophy (FSHD) and Spinal Muscular Atrophy (SMA). These trials aim to evaluate the drug’s safety, efficacy, and pharmacological properties when used alone or in combination with other treatments.

Table of Contents

What is HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN LATENT MYOSTATIN?

HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN LATENT MYOSTATIN is an innovative medication being developed to treat muscle-wasting disorders. This complex name describes a type of drug called a monoclonal antibody, which is designed to target a specific protein in the body[1]. In simpler terms, it’s a specially engineered molecule that aims to help people with certain muscle diseases.

This drug is also known by several other names, including:

  • RO7204239
  • GYM329
  • RG 6237

These names are often used interchangeably in medical literature and clinical trials[1].

How does it work?

The medication works by targeting a protein called myostatin. Myostatin is a natural protein in our bodies that limits muscle growth. By blocking the action of myostatin, this drug aims to promote muscle growth and prevent muscle wasting[1].

Specifically, this antibody targets the “latent” form of myostatin. This means it’s designed to block myostatin before it becomes active in the body, potentially making it more effective than other approaches[1].

What conditions does it treat?

Current clinical trials are focusing on two main conditions:

  1. Facioscapulohumeral Muscular Dystrophy (FSHD): This is a genetic disorder that causes progressive muscle weakness, primarily affecting the face, shoulder blades, and upper arms[1].
  2. Spinal Muscular Atrophy (SMA): This is another genetic disorder that affects motor neurons, leading to muscle weakness and atrophy[2].

These conditions can significantly impact a person’s quality of life, making everyday tasks difficult. The hope is that this new medication could help improve muscle strength and function in people with these disorders.

Current Clinical Trials

Two major clinical trials are currently underway to test this medication:

  1. FSHD Trial: This is a Phase II study evaluating the drug’s effects in patients with Facioscapulohumeral Muscular Dystrophy. The study is looking at how the drug affects muscle volume, safety, and various measures of muscle function[1].
  2. SMA Trial (MANATEE): This is a Phase III study investigating the drug in combination with another medication called risdiplam for patients with Spinal Muscular Atrophy. This study is particularly interested in how the combination therapy affects motor function in patients with SMA[2].

Both trials are randomized, placebo-controlled, and double-blind, which means neither the patients nor the researchers know who is receiving the actual drug versus a placebo. This helps ensure the results are as unbiased as possible[1][2].

How is it administered?

The medication is given as a subcutaneous injection. This means it’s injected just under the skin, similar to how insulin is administered for diabetes. The exact dosage and frequency of injections are still being determined through the clinical trials[1][2].

Safety and Side Effects

As with any new medication, safety is a primary concern. The clinical trials are closely monitoring for any side effects or adverse reactions. Some of the things they’re watching for include:

  • Injection site reactions
  • Changes in vital signs
  • Abnormalities in laboratory tests, ECG, or echocardiogram
  • Any other unexpected side effects

It’s important to note that the full safety profile of this medication won’t be known until the clinical trials are completed and the results are analyzed[1][2].

Future Prospects

If the clinical trials show positive results, this medication could potentially offer new hope for patients with muscle-wasting disorders like FSHD and SMA. However, it’s important to remember that drug development is a long and complex process. Even if the trials are successful, it may be several years before the medication becomes widely available[1][2].

Patients and families affected by these conditions should stay in touch with their healthcare providers for the latest updates on this and other emerging treatments.

Aspect FSHD Trial SMA Trial
Drug Name RO7204239 RO7204239 (in combination with risdiplam)
Target Condition Facioscapulohumeral Muscular Dystrophy Spinal Muscular Atrophy
Age Range 18-65 years 2-25 years (varies by cohort)
Primary Objectives Evaluate PD effects, safety, and PK parameters Evaluate safety, PK, PD, and efficacy
Key Measurements Contractile muscle volume, adverse events, serum concentrations Motor function scores, muscle mass, adverse events
Administration Route Subcutaneous injection Subcutaneous injection
Study Design Randomized, placebo-controlled, double-blind Two-part, randomized, placebo-controlled, double-blind

FAQ

  • What is RO7204239? RO7204239 is a humanised IgG1 monoclonal antibody that targets human latent myostatin. It is being investigated as a potential treatment for muscular disorders such as Facioscapulohumeral Muscular Dystrophy (FSHD) and Spinal Muscular Atrophy (SMA).
  • What are the main objectives of these clinical trials? The main objectives of these trials include evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RO7204239. In some studies, it is being tested alone, while in others, it is being investigated in combination with other drugs like risdiplam.
  • Who can participate in these clinical trials? Eligibility criteria vary between trials. For the FSHD study, participants must be between 18 and 65 years old with genetically confirmed FSHD. For the SMA study, age ranges from 2 to 25 years, depending on the specific cohort, and participants must have a confirmed genetic diagnosis of 5q-autosomal recessive SMA.
  • How is the drug administered? RO7204239 is administered through subcutaneous injection. The dosage and frequency of administration may vary depending on the specific trial and treatment group.
  • What are some of the key measurements being taken in these trials? Key measurements include changes in muscle volume and fat fraction as assessed by MRI, changes in motor function scores, safety assessments such as adverse events and laboratory tests, and pharmacokinetic parameters of the drug. Some trials also measure changes in myostatin levels and assess the presence of anti-drug antibodies.

Ongoing Clinical Trials on Humanised Igg1 Monoclonal Antibody Against Human Latent Myostatin

  • Study on the Effects of RO7204239 and Tirzepatide for Weight Loss in Patients with Obesity or Overweight with a Weight-Related Health Issue

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Poland Spain

  • Study on the Effects and Safety of RO7204239 for Patients with Facioscapulohumeral Muscular Dystrophy

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Denmark Italy

Glossary

  • Facioscapulohumeral Muscular Dystrophy (FSHD): A genetic disorder characterized by muscle weakness and loss of muscle tissue, primarily affecting the face, shoulder blades, and upper arms.
  • Spinal Muscular Atrophy (SMA): A genetic disorder affecting muscle strength and movement due to a loss of specialized nerve cells in the spinal cord and brainstem.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They are used to treat various diseases, including some types of cancer.
  • Myostatin: A protein that acts to inhibit muscle growth. Blocking myostatin is a potential strategy for treating muscle-wasting disorders.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique that uses strong magnetic fields and radio waves to produce detailed images of the inside of the body.
  • Contractile Muscle Volume (CMV): The volume of muscle tissue capable of contracting, often measured using imaging techniques like MRI.
  • Anti-Drug Antibodies (ADAs): Antibodies produced by the immune system in response to a therapeutic drug, which can potentially affect the drug's efficacy or safety.
  • Risdiplam: A medication used to treat spinal muscular atrophy, which works by increasing the production of a protein necessary for the survival of motor neurons.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-ro7204239-for-patients-with-facioscapulohumeral-muscular-dystrophy/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-efficacy-of-ro7204239-and-risdiplam-for-patients-with-spinal-muscular-atrophy/